Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > did not like

<< Previous

Bullboard Posts

Next >>

Comment by enriquesuaveon Jun 30, 2021 6:09pm

217 Views

Post# 33477608

RE:RE:did not like

We already knew about those 9 patients. I believe only 2 or 3 patients from the first set of 12 PH2 patients got a 2nd treatment which was optimized, plus now patients 13 and on got 1st optimized treatment. Will they post a replay of AGM I came in a bit late.

enriquesuave wrote: That was the 8 from the initial 12 undertreated patients and probably patient number 4 from PH1 who also didn't receive an Optimized treatment. We will need to see the data on optimized treated patients once available. Another 3 at next Quarterly report imo

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"